Esta buscando: Levodopa

Proveedor: Cayman Chemical

Descripción: Levodopa

MSDS

Numero del catalogo: (PHR1271-500MG)

Proveedor: Merck

Descripción: Organic Standard, Levodopa

UOM: 1 * 500 mg

Promoción

Proveedor: Thermo Scientific

Descripción: Levodopa ≥98%

MSDS Certificados

Proveedor: Thermo Scientific

Descripción: Levodopa 99%

MSDS

Proveedor: TCI

Descripción: Levodopa ≥98.0% (by HPLC, titration analysis)

Proveedor: USP

Descripción: USP Reference Standards are specified for use in conducting official USP–NF tests and assays. USP also provides Reference Standards specified in the Food Chemicals Codex as well as authentic substances—high-quality chemical samples—as a service to analytical, clinical, pharmaceutical and research laboratories. To confirm accuracy and reproducibility, USP Reference Standards are rigorously tested and evaluated by multiple independent laboratories including USP, commercial, regulatory, and academic labs. USP also provide publicly available, official documentary standards for pharmaceutical ingredients in the USP–NF that link directly with our primary reference standards.

Proveedor: MP Biomedicals

Descripción: L-3,4-Dihydroxyphenylalanine (L-DOPA), an anti-Parkinsonian agent, is the natural isomer of the immediate precursor to dopamine. L-DOPA is the product of the hydroxylation of L-tyrosine by tyrosine hydroxylase in brain and in adrenal medulla.

Numero del catalogo: (PROOBP213)

Proveedor: LGC Standards PROMOCHEM

Descripción: Levodopa

UOM: 1 * 100 mg

Promoción

Numero del catalogo: (PROOICRS0334)

Proveedor: LGC Standards PROMOCHEM

Descripción: Levodopa

UOM: 1 * 100 mg

Promoción

Numero del catalogo: (BSENR-183-50)

Proveedor: Biosensis

Descripción: LRRK2 is a member of the leucine-rich repeat kinase family. Its role is yet unknown but it may play a role in the phoshorylation of proteins central to parkinson diseases. LRRK2 contains an ankryin repeat region, a leucine-rich repeat (LRR) domain, a kinase domain, a DFG-like motif, a RAS domain, a GTPase domain, a MLK-like domain and a WD40 domain. LRRK2 is present in the cytoplasm but also associates with the mitochondrial outer membrane. Defects in LRRK2 are the cause of Parkinson disease 8 (PARK8). Parkinson disease is characterised by bradykinesia, resting tremor, muscular rigidity and postural instability, as well as by a clinically significant response to treatment with levodopa. The pathology involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain. PARK8 is an autosomal-dominant late-onset parkinsonism, characterized by onset from 50 to 65 years, with slow progression and relatively benign course.

UOM: 1 * 50 µG

Promoción

Numero del catalogo: (PROOMM0262.00)

Proveedor: LGC Standards PROMOCHEM

Descripción: Levodopa

UOM: 1 * 500 mg

Promoción

Numero del catalogo: (PHR2096-100MG)

Proveedor: Merck

Descripción: LEVODOPA RELATED COMPOUND B 1 * 100 mg

UOM: 1 * 100 mg

Promoción

Numero del catalogo: (PHR2095-100MG)

Proveedor: Merck

Descripción: LEVODOPA RELATED COMPOUND A 1 * 100 mg

UOM: 1 * 100 mg

Promoción

Numero del catalogo: (PROOLGCFOR0262.00)

Proveedor: LGC Standards PROMOCHEM

Descripción: LEVODOPA 1 * 10 mg

UOM: 1 * 10 mg

Promoción